Clear Harbor Asset Management LLC Invests $3.71 Million in IQVIA Holdings Inc. $IQV

Key Points

• Clear Harbor Asset Management initiated a $3.71 million position in IQVIA by purchasing 19,220 shares during the second quarter. Institutional investors collectively own 89.62% of the company.
• Analysts maintain a positive outlook, with IQVIA receiving a consensus “Moderate Buy” rating and an average price target of $241.88; JPMorgan recently raised its target to $285.
• IQVIA exceeded quarterly earnings and revenue expectations, reporting $3.15 in EPS and $4.37 billion in revenue, while authorizing a $2 billion share-repurchase program covering up to 6.8% of outstanding shares.

Clear Harbor Asset Management LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,220 shares of the medical research company's stock, valued at approximately $3,714,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter valued at about $2,811,292,000. Boston Partners bought a new stake in shares of IQVIA during the 3rd quarter worth about $676,698,000. Norges Bank bought a new stake in shares of IQVIA during the 4th quarter worth about $497,445,000. Victory Capital Management Inc. lifted its stake in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock worth $377,670,000 after acquiring an additional 1,614,063 shares during the period. Finally, Orbis Allan Gray Ltd boosted its holdings in shares of IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company's stock valued at $428,525,000 after acquiring an additional 933,554 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IQV. Mizuho boosted their target price on IQVIA from $215.00 to $230.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Weiss Ratings raised IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. Barclays restated an "overweight" rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, JPMorgan Chase & Co. raised their target price on IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Trading Up 1.6%

Shares of NYSE IQV opened at $260.17 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $260.40. The company has a market cap of $42.82 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. The business has a fifty day simple moving average of $213.32 and a 200-day simple moving average of $187.52.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA's revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

Insider Activity

In other news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company's stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the business's stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 12,913 shares of company stock valued at $3,098,793. Corporate insiders own 1.70% of the company's stock.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source